1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,160 | 1,280 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | BOAN BIOTECH (06955): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 31 MAY 2024 (APPLICABLE TO HOLDERS OF H SHARES) | 1 | HKEx | ||
| Mo | BOAN BIOTECH (06955): (1) 2023 REPORT OF THE BOARD OF DIRECTORS (2) 2023 REPORT OF THE BOARD OF SUPERVISORS (3) 2023 ANNUAL REPORT (4) PROPOSED RE-ELECTION ... | 1 | HKEx | ||
| Mo | BOAN BIOTECH (06955): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Mo | BOAN BIOTECH (06955): 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| Mo | BOAN BIOTECH (06955): ANNUAL REPORT 2023 | - | HKEx | ||
| 15.04. | FAST NEWS: Boan Bio pledges shares as collateral for $41 million loan | 1 | Bamboo Works | ||
| 12.04. | BOAN BIOTECH (06955): ANNOUNCEMENT - LOAN FACILITY | 1 | HKEx | ||
| 08.04. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT PHASE 3 CLINICAL TRIAL COMPLETED IN CHINA FOR AFLIBERCEPT INTRAVITREOUS INJECTION (BA9101) AND BLA TO BE ... | 1 | HKEx | ||
| 25.03. | BOAN BIOTECH (06955): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023 | - | HKEx | ||
| 12.03. | BOAN BIOTECH (06955): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 08.03. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT PHASE 3 CLINICAL TRIAL COMPLETED IN CHINA FOR DULAGLUTIDE INJECTION (BA5101) AND BLA TO BE FILED | 1 | HKEx | ||
| 29.02. | BOAN BIOTECH (06955): NOTIFICATION LETTER TO NON-REGISTERED H SHAREHOLDERS AND REPLY FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 29.02. | BOAN BIOTECH (06955): NOTIFICATION LETTER TO REGISTERED H SHAREHOLDERS AND REPLY FORM - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 30.01. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT AUTHORIZATION TO ZENCORE BIOLOGICS TO USE BA-HIEXCELL STABLE CELL LINE DEVELOPMENT PLATFORM | 1 | HKEx | ||
| 26.01. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT FOR BA2101 IN THE TREATMENT OF RESPIRATORY SYSTEM DISEASES | 1 | HKEx | ||
| 24.01. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT BOTH BA1105 AND BA1301 BEING GRANTED ORPHAN DRUG DESIGNATIONS FOR TREATMENT OF GASTRIC CANCER BY FDA | - | HKEx | ||
| 17.01. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT THE COMPANY HAS OBTAINED GMP CERTIFICATION FOR BOYUNO FROM THE BRAZILIAN AGENCIA NACIONAL DE VIGILANCIA SANITARIA | - | HKEx | ||
| 04.01. | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT ENROLLMENT OF SUBJECTS COMPLETED FOR INTERNATIONAL MULTI-CENTER COMPARATIVE CLINICAL (PHASE 3) STUDY OF DENOSUMAB ... | 1 | HKEx | ||
| 29.12.23 | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT VOLUNTARY LOCK-UP UNDERTAKINGS BY CERTAIN SHAREHOLDERS | 1 | HKEx | ||
| 27.12.23 | BOAN BIOTECH (06955): VOLUNTARY ANNOUNCEMENT BOTH BA1105 AND BA1301 BEING GRANTED ORPHAN DRUG DESIGNATIONS FOR TREATMENT OF PANCREATIC CANCER BY THE FDA | 1 | HKEx |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,940 | +0,90 % | DAX-Check LIVE: Bilanzenflut - Adidas, Covestro, Mercedes-Benz, MTU, Qiagen, Volkswagen Vz., Vonovia | Der DAX ist gestern nach anfänglichen Gewinnen ins Minus gerutscht. Am Ende des Tages ging er mit einem Verlust von 0,24 Prozent aus dem Handel. Worauf es jetzt für den DAX ankommt, erläutert Thomas... ► Artikel lesen | |
| EVOTEC | 9,760 | -1,36 % | Evotec, Vidac Pharma, BioNTech - das Milliardenrennen um die Krebstherapie | Die Onkologie steht an der Schwelle zu einer goldenen Ära. Getrieben von einer Zunahme der Krebserkrankungen und beeindruckenden wissenschaftlichen Fortschritten, darunter Gen- und Immuntherapien, eröffnet... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 45,110 | +4,06 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates | - Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter - - Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 37,400 | +3,03 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update | KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294 (TYK2)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 8,000 | -6,98 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in... ► Artikel lesen | |
| DYNE THERAPEUTICS | 26,080 | +0,31 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights | - Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne... ► Artikel lesen | |
| NUVALENT | 70,35 | -2,95 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,840 | +0,57 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| CG ONCOLOGY | 36,270 | -8,18 % | CG Oncology Inc.: Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | - Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today... ► Artikel lesen | |
| ANNEXON | 4,880 | +4,72 % | Annexon (ANNX) to Report Q1 Earnings: What's in the Cards? | ||
| JANUX THERAPEUTICS | 64,78 | +3,76 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SANA BIOTECHNOLOGY | 10,440 | +6,75 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| CABALETTA BIO | 12,390 | -1,67 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,270 | +2,83 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 26,450 | +3,40 % | Navigating 7 Analyst Ratings For Avidity Biosciences |
SHANDONG BOAN BIOTECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,030 (-2,54 %) liegt der Kurs bei 1,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
